摘要目的 以乙肝标志物核心抗体阳性的患者为分析对象,定性检测抗-HBcIgM,探讨其在乙肝治疗恢复期的临床指导意义[1-2].方法 使用固相放射免疫分析法定性检测抗-HBcIgM.结果 统计学分析采用标准化法比较.感染期模式组IgM平均阳性率44.2%.非治疗患者IgM阳性率62.9%,高于组平均阳性率.治疗患者lgM阳性率28.8%,低于组平均阳性率;恢复期模式组IgM平均阳性率10.4%.非治疗患者IgM阳性率12.5%.高于组平均阳性率.治疗患者IgM阳性率0,低于组平均阳性率;88例复检者,IgM阳性率首次检测83%,第二次27.3%,第三次17.6%.治疗后,复检者乙肝两对半模式好转率20.5%,IgM检测阴性好转率69.3%.结论 抗-HbcIgM与乙肝的预后恢复呈正相关,当抗病毒药物治疗有效时,IgM快速转阴,治疗期检测IgM能更早更准确地掌握乙肝的恢复和预后[3-4].

abstractsObjective To explore the clinical significance of anti-HBc IgM in hepatitis B during the recovery period by qualitatively detecting this IgM in patients with HBcAb positive. Methods Anti-HBc IgM was detected by using radioimmunoassay. Results Standardized comparison was applied in statistical analysis. In the infective stage, the positive rate of IgM was higher in non-treatment group than in the pattern group ( 62.9% vs. 44.2% ) while it is lower in treatment group than in the pattern group ( 28.8% vs. 44.2% ). In recovery stage, the positive raate of IgM was higher in non-treatment group but was lower in treatment group than in the pattern group( 12.5% vs. 0.0% vs. 10.4% ). The first detection rate was 83%, the second 27.3%, and the third 17.6% in 88 patients with repeat examination. After treatment, the improvement rate of HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb was 20.5% and the negative rate of IgM was 69.3%. Conclusions Anti-HBc IgM is positively associated with the prognosis and recovery of hepatitis B; when antiviral agents are effective, IgM rapidly becomes negative. Detection of IgM during treatment can more accurately predict the recovery and prognosis of hepatitis B.